Prateek Arora, Director of Product Management, PharmEasy
Prateek Arora, Director of Product Management at PharmEasy, is a customer-centric innovator with a multifaceted background spanning product management, strategy, consulting, advisory, and digital marketing. He engages in a conversation with Thiruamuthan, Correspondent, The Industry Outlook and reflects upon how technological trends are propelling the growth of the pharmaceutical industry.
The pharmaceutical industry in India stands at the cusp of a technological revolution and has been growing at a rapid pace, with the country being one of the largest producers of generic drugs in the world. According to a recent EY FICCI report, the Indian pharmaceutical market is estimated to touch $130 billion in value by the end of 2030. Meanwhile, the global market size of pharmaceutical products is estimated to cross over the $1 trillion mark in 2023. The Indian pharmaceutical industry has grown at a compounded annual growth rate (CAGR) of ~11% in the domestic market and ~16% in exports over the last two decades. The Indian pharma industry ranks third by volume and thirteenth by value globally.
This decade holds a positive outlook for India’s pharmaceutical industry, with a deeper focus on quality manufacturing, affordability of drugs, adoption of groundbreaking innovations and technology, and seamless integration of digital solutions. This synergy of technology and healthcare is reshaping the landscape of drug discovery, manufacturing, distribution, and patient care, which has helped it to improve its efficiency and productivity. Simultaneously, e-pharmacy companies have emerged as game-changers, leveraging cutting-edge technologies to provide convenient and accessible healthcare solutions to end-consumers and just-in-time stock replenishment to retailers.
AI and ML are at the forefront of transforming drug discovery and development. They facilitate predictive analytics in identifying potential drug candidates, significantly expediting the process of bringing new medications to market. India's pharmaceutical companies are harnessing AI algorithms to analyze vast datasets, accelerating the identification of drug targets, optimizing clinical trial designs, predicting drug efficacy, and reducing drug development costs. AI can also help to identify patients who are at risk of developing certain diseases, allowing doctors to provide early intervention and prevent the onset of these diseases. For instance, a few AI-driven platforms are revolutionizing drug discovery by using deep learning to design novel molecules.
The implementation of blockchain technology is enhancing transparency, traceability, and security in the pharmaceutical supply chain and preventing counterfeit drugs from entering the market. In India, where ensuring authenticity of medicines is crucial, blockchain offers a decentralized and immutable ledger to track the movement of drugs from manufacturers to consumers. A few Indian companies are pioneering blockchain-based solutions, minimizing counterfeit drugs and ensuring compliance with regulatory standards.
Big data analytics is revolutionizing clinical trials by enabling the analysis of diverse patient populations and real-time data monitoring. Pharmaceutical companies in India are leveraging advanced analytics to optimize trial protocols, identify suitable patient cohorts, and predict potential outcomes. This approach expedites the development process while ensuring better drug efficacy and safety. A few Indian platforms provide access to real-world data, enabling companies to design more efficient and patient-centric trials.
Telehealth and on-demand diagnostics solutions have gained momentum, especially in India's remote areas, offering accessible healthcare services. With the integration of IoT devices and wearables, e-pharmacy companies are enabling remote patient monitoring, allowing for continuous tracking of vital signs and medication adherence. This technological trend not only enhances patient care but also facilitates data-driven healthcare interventions. A few Indian HealthTech startups provide teleconsultation and diagnostics services, connecting patients with healthcare providers seamlessly. Some older healthcare providers like Apollo and Dr. Lal PathLabs are also revamping their tech infrastructure to provide omnichannel services.
Advancements in pharmacogenomics are steering the industry toward personalized medicine. By analyzing an individual's genetic makeup, lifestyle, and environment, pharmaceutical companies can tailor treatments for specific patient populations, optimizing drug efficacy and reducing adverse reactions. Some India-based companies are providing genetic testing services, empowering healthcare professionals to make informed decisions about personalized treatment plans.
E-pharmacy companies in India are continually innovating to enhance customer experience and streamline operations. Integration of AI-powered chatbots for customer support, automated prescription verifications, and drone-based deliveries in remote areas are becoming prevalent. PharmEasy, for instance, uses AI algorithms for predictive inventory management; ensuring medicines are available and accessible when needed by end-consumers.
The evolving regulatory landscape demands stringent adherence to compliance standards. RegTech solutions are aiding pharmaceutical companies and e-pharmacies in navigating complex regulatory frameworks efficiently. These technologies automate compliance processes, ensuring adherence to local and international regulations and simplifying compliance management for pharmaceutical entities.
Digitalization and automation are also transforming the pharmaceutical industry in India. The use of digital technologies such as cloud computing, big data analytics, and the Internet of Things (IoT) is helping companies to streamline their operations and improve their production, warehouse storage, and delivery efficiency. Automation is also being used to reduce errors and improve quality control in drug manufacturing. For instance, Retailio has automated its fulfillment operations from inventory procurement to last-mile retailer delivery operations using smart tagging with RFID and QR Codes for accurate inventory management and timely delivery tracking.
3D printing is another technological trend that is transforming the pharmaceutical industry in India. 3DP can help reduce drug development costs by enabling rapid prototyping and manufacturing of drugs. 3DP can be used to create customized drug formulations and artificial limbs that are tailored to individual patients’ needs. This approach can help to improve patient outcomes by providing more personalized care.
For example, Aprecia Pharmaceuticals has developed a 3D-printed drug called Spritam for epilepsy treatment.
IoMT is a network of medical devices that can communicate with each other and share data. IoMT can improve patient outcomes by providing real-time monitoring of vital signs, remote diagnosis, and telemedicine.
The convergence of technology and pharmaceuticals is propelling the industry toward unprecedented growth and innovation. In India, these technological trends are reshaping drug discovery, manufacturing, distribution, and patient care, while e-pharmacy companies are revolutionizing accessibility and convenience in healthcare services. Embracing these technological advancements will be pivotal for companies to stay competitive and cater to the evolving needs of the pharma ecosystem, ultimately benefiting patients and stakeholders alike.
As Indian pharma 'C' level executives navigate this dynamic landscape, embracing and leveraging these technological trends will not only drive operational efficiency but also foster groundbreaking advancements, ensuring the continual growth and evolution of the pharmaceutical industry in India.
Through the infusion of these technologies, the pharmaceutical industry and e-pharmacy companies are poised to unlock new frontiers of innovation, making healthcare more accessible, efficient, and tailored to individual needs in the Indian market.
.jpg)
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")